You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

111 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
Jan 2025
Drug
Other Name(s): Vectibix®
Jan 2025
Drug
Other Name(s): Trecondyv®
Jan 2025
Drug
Other Name(s): Keytruda®
Jan 2025
Drug
Other Name(s): Sprycel®
Feb 2025
Drug
Other Name(s): Firmagon®
Feb 2025
Drug
Other Name(s): Lorbrena®
Feb 2025
Drug
Other Name(s): Inqovi®
Feb 2025
Drug
Other Name(s): Tukysa™
Feb 2025
Drug
Other Name(s): Jemperli
Feb 2025
Drug
Other Name(s): Opdualag™
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025

Pages